Akkaramongkolporn et al., 2003 - Google Patents
Dual ambroxal and chlorpheniramine resinate as an alternative carrier in concurrent resinate administrationAkkaramongkolporn et al., 2003
View PDF- Document ID
- 16801638991723851668
- Author
- Akkaramongkolporn P
- Ngawhirunpat T
- Publication year
- Publication venue
- Die Pharmazie-An International Journal of Pharmaceutical Sciences
External Links
Snippet
Two classical resinates, ambroxal (AMX) resinate and chlorpheniramine (CPM) resinate, and a novel formulation of dual AMX and CPM resinate were prepared by the batch method. The dissolution behavior of the drug from the classical resinates, a mixture of two classical …
- 229940107080 Chlorpheniramine 0 title abstract description 102
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48169—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule
- A61K47/48176—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule the organic macromolecular compound has been obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2256442C2 (en) | Consumed film for in-mouth holding and a method for preparation of consumed film | |
US12201720B2 (en) | Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release | |
ES2254274T3 (en) | HYDROGEL HETERODISPERSOS SYSTEMS OF SUSTAINED LIBERATION FOR INSOLUBLE PHARMACOS. | |
Guo et al. | Ion-exchange resins as drug delivery carriers | |
EP2694038B1 (en) | Pharmaceutical composition | |
US20080081072A1 (en) | Resin-complex granulation for water-soluble drugs and associated methods | |
US4721709A (en) | Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions | |
CN102885798B (en) | Orally disintegrating tablet | |
Shukla et al. | Fabrication and evaluation of taste masked resinate of risperidone and its orally disintegrating tablets | |
PL175814B1 (en) | Solid dosed form of prolonged release for oral administration and method of obtaining same, | |
HU218661B (en) | A method for the preparation of pharmaceutical forms comprising a complex of pharmaceutically active ionic drug and ion exchange resin | |
EP0367746A2 (en) | Sustained release drug-resin complexes | |
SA01210741B1 (en) | Stable extended release oral dogase composition | |
PL194526B1 (en) | Improved fast disintegrating tablet | |
HU227381B1 (en) | Pharmaceutical composition containing slightly water-soluble drugs with immediate release core and instained release coating | |
JP2002534374A (en) | Multiparticulate oral dosage form | |
JPS63165318A (en) | Light-stable nifedipin concentrate and manufacture | |
DE69419281T2 (en) | Flavor-masked solid preparation and manufacturing method | |
Lorenzo-Lamosam et al. | Development of a microencapsulated form of cefuroxime axetil using pH-sensitive acrylic polymers | |
US4780322A (en) | Method of producing slow-release pharmaceutical forms | |
Akkaramongkolporn et al. | Dual ambroxal and chlorpheniramine resinate as an alternative carrier in concurrent resinate administration | |
KR20050082038A (en) | Tamsulosin hydrochloride composition for oral administration and controlled-release granule formulation thereof | |
JPH05504574A (en) | Composition | |
JPS609697B2 (en) | formulation | |
Pisal et al. | Drug release properties of polyethylene-glycol-treated ciprofloxacin-Indion 234 complexes |